Table 2.
Response to treatment with pembrolizumab as assessed by irRECIST in four tumor-specific cohorts
| SCC of the skin | ACC | CUP | P–P | |
| Number of patients treated | 19 | 15 | 22 | 9 |
| Number of patients assessed for NPR at 27 weeks (%) | 14 (74) | 13 (87) | 12 (55) | 7 (78) |
| NPR at 27 weeks (%) | 5 (36) | 4 (31) | 4 (33) | 3 (43) |
| Number of patients assessed for ORR and CBR (%) | 16 (84) | 13 (87) | 13 (59) | 8 (89) |
| Complete response, n (%) | 1 (6) | 0 (0) | 0 (0) | 0 (0) |
| Partial response, n (%) | 4 (25) | 2 (15) | 3 (23) | 0 (0) |
| Stable disease, n (%) | 2 (13)* | 6 (46)* | 4 (31) | 6 (75) |
| Progressive disease, n (%) | 9 (56) | 5 (38) | 6 (46) | 2 (25) |
| ORR, n (%) | 5 (31) | 2 (15) | 3 (23) | 0 (0) |
| CBR, n (%) | 6 (38) | 7 (54) | 7 (54) | 6 (75) |
*One patient in each group had stable disease <4 months and was thus not included in the calculation of CBR.
ACC, adrenocortical carcinoma; CBR, clinical benefit rate; CUP, carcinoma of unknown primary; irRECIST, immune-related Response Evaluation Criteria in Solid Tumors; NPR, non-progression rate; ORR, objective response rate; P–P, paraganglioma–pheochromocytoma; SCC, squamous cell carcinoma.